|Numéro de publication||WO1990011375 A1|
|Type de publication||Demande|
|Numéro de demande||PCT/US1990/001535|
|Date de publication||4 oct. 1990|
|Date de dépôt||26 mars 1990|
|Date de priorité||27 mars 1989|
|Autre référence de publication||CA2012983A1, EP0465528A1|
|Numéro de publication||PCT/1990/1535, PCT/US/1990/001535, PCT/US/1990/01535, PCT/US/90/001535, PCT/US/90/01535, PCT/US1990/001535, PCT/US1990/01535, PCT/US1990001535, PCT/US199001535, PCT/US90/001535, PCT/US90/01535, PCT/US90001535, PCT/US9001535, WO 1990/011375 A1, WO 1990011375 A1, WO 1990011375A1, WO 9011375 A1, WO 9011375A1, WO-A1-1990011375, WO-A1-9011375, WO1990/011375A1, WO1990011375 A1, WO1990011375A1, WO9011375 A1, WO9011375A1|
|Inventeurs||Sydney Brenner, Jeffrey Allan Miller|
|Déposant||E.I. Du Pont De Nemours And Company|
|Exporter la citation||BiBTeX, EndNote, RefMan|
|Citations de brevets (2), Citations hors brevets (1), Référencé par (22), Classifications (6), Événements juridiques (6)|
|Liens externes: Patentscope, Espacenet|
TITLE PROCESS FOR NUCLEIC ACID DETECTION BY BINARY AMPLIFICATION FIELD OF INVENTION
This invention relates to the detection of nucleic acid sequences and more specifically to a process of combining the products from the amplification of two portions of a target nucleic acid sequence. BACKGROUND OF THE TNVENTT N
The development of practical nucleic acid hybridization methods which can be used for detecting nucleic acid sequences of interest has been limited by several factors . These include lack of sensitivity, complexity of procedure, and the desire to convert from radiometric to nonradiometric detection methods . A variety of methods have been investigated for the purpose of increasing the sensitivity nonradiometric procedures . In one general approach, improvements in the total assay procedure have been examined, with concomitant effects on the issues of complexity and nonradiometric detection. In another approach, methods which increase the amount of nucleic acid to be detected by such assays have been pursued. U.S. Patent 4,358,535, issued to Falkow, describes a method of culturing cells to increase their number and thus the amount of nucleic acid of the organism suspected to be present, depositing the sample onto fixed support, and then contacting the sample with a labeled probe, followed by washing the support and detecting the label. One drawback to this method is that without culturing the organism first, the assay does not have adequate sensitivity. Adding a culture step, however, is time consuming and not always successful. Maniatis et al., Molecular Cloning: A
SUBSTITUTE SHET Laboratory Manual . Cold Spring Harbor Laboratory, pp.390-401 (1982), describe a method in which a nucleic acid of interest is amplified by cloning it into an appropriate host system. Then, when the host organism replicates in culture, the nucleic acid of interest is also replicated. This method also suffers from the requirement to perform a culture step and thus provides for a procedure that is time consuming and complicated. An alternative approach to increasing the quantity of nucleic acids of organisms has been described in U.S. patents 4,683,202 and 4,683,195. These patents disclose "a process for amplification and detection of any target nucleic acid sequence contained in a nucleic acid or mixture thereof". This process employs an in vitro cycling mechanism which doubles the nucleic acid sequence to be amplified after each cycle is complete. This is carried out by separating the complementary strands of the nucleic acid sequence to be amplified, contacting these strands with excess oligonucleotide primers and extending the primers by enzymatic treatment to form primer extension products that are complementary to the nucleic acid annealed with each primer. The process is then repeated as many times as is necessary. An advantage of this method is that it can rapidly produce large quantities of a small portion of the sequence of the nucleic acid of an organism of interest. A disadvantage of this method is that the detection of the nucleic acids produced, using a direct assay method, is complicated in that the amplification process can produce nucleic acid sequences which are not faithful copies of the original nucleic acid which was to be copied. These erroneous nucleic acid sequences can provide false positives in the assay which increase the background noise and thus decrease the sensitivity of the entire method. Numerous DNA probe assays have been described in the past for the detection of nucleic acids of interest. Falkow's method (above) first renders the target nucleic acid single-stranded and then immobilizes it onto a solid support. A labeled probe which is complementary to the target nucleic acid is then brought into contact with the solid support. Any excess probe is washed away and the presence of the label in the resulting hybrid is determined. A disadvantage of this method is that it is time consuming and cumbersome. The assay steps, i.e., hybridization and washing steps are carried out in a sealed pouch which contains the membrane (solid support) as well as the buffer solution.
Hill et al., WO 86/05815, describe a variation of the above assay format employing nitrocellulose coated magnetic particles to which the target DNA is affixed, followed by direct hybridization with a biotinylated probe and detection using a streptavidin-conjugated reporter. Dunn et al. , Cell, Vol. 12, 23-36 (1977), describe a different hybridization format which employs a two- step sandwich assay method employing polynucleotide probes in which the target nucleic acid is mixed with a solution containing a first or capture probe which has been affixed to a solid support. After a period of time, the support is washed and a second or reporter (labeled) probe, also complementary to the target nucleic acid but not to the capture probe, is added and allowed to hybridize with the capture probe - target nucleic acid complex. After washing to remove any unhybridized reporter probe, the presence of the reporter probe, hybridized to the target nucleic acid, is detected.
Ranki et al. U.S. Patent 4,563,419, disclose EPA 0 154 505, W086/03782, and EPA 0 200 113. It is to be recognized that all of these employ an assay procedure in which the first or capture probe is immobilized onto a solid support prior to hybridization. A further variation has been described in German Preliminary Published Application 3,546,312 Al. This method, like that described by Ranki et al., employs a capture probe and a reporter probe which hybridize to distinct portions of the target nucleic acid. The target nucleic acid is contacted in solution by the two probes. The first, or capture probe, contains a binding component, such as biotin, that is capable of binding with a receptor component, such as streptavidin, which has been affixed to a solid support. After formation of the capture probe - target nucleic acid - reporter probe complex, a streptavidin-modified solid support is added. Any unhybridized reporter probe is washed away followed by the detection of the. label incorporated into the complex bound to the solid support. An advantage of this technique over that disclosed by Ranki et al. is that the hybridization, which takes place in solution, is favored kinetically. Some disadvantages are that the length of the target nucleic acid affects the overall efficiency of the reaction which decreases with increasing target nucleic acid length. Also, sandwich nucleic acid probe assays, whether heterogeneous two- step or one-step, or utilizing solution hybridization, are not as sensitive as the direct assay method.
A disadvantage of all of these techniques relates to the need to employ a specific hybridization step in order to obtain the necessary specificity and thus proper identification of the target nucleic acid sequence of interest.
DISCLOSURE OF THE INVENTION
The nucleic acid assay of this invention for the detection and/or measurement of a preselected nucleic acid sequence in a sample suspected of including a nucleic acid containing said preselected sequence comprises the steps of:
(A) rendering the target nucleic acid single- stranded;
(B) amplifying two specific nucleic acid sequences contained within the preselected nucleic acid sequence, said specific nucleic acid sequences being positioned such that when either- sequence is amplified under amplification conditions, the extension product of either sequence cannot serve as a template for the synthesis of the other sequence,by (1) treating the strands with two sets of two oligonucleotide primers, one set for each different specific sequence being amplified, under conditions such that for each different sequence being amplified an extension product of each primer is synthesized which is complementary to each nucleic acid strand, wherein said sets of primers are selected so as to be sufficiently complementary to the different strands of each specific sequence to hybridize therewith such that the extension products synthesized from one primer from each of the two sets of primers, when separated from their respective complements, can serve as templates for the synthesis of the extension products of the other primer from each of the two sets of primers; wherein one of the primers of each set of primers contains a LoxP sequence at its 5'-end; (2) separating the primer extension products from the templates on which they were synthesized to produce single-stranded molecules; (3) treating the single-stranded molecules generated from step (2) with the two sets of primers of step (1) under conditions that primer extension products are synthesized using each of the single strands produced in step (2) as templates; and (4) repeating steps (2) and (3) to produce sufficient primer extension products for detection and/or measurement; (C) treating the products of the two separate amplification reactions by the recombinase enzyme Cre; and (D) detecting and/or measuring that product of step (C) resulting from the two separate amplification reactions.
DETAILED DESCRIPTION OF THE INVENTION
The nucleic acid assay of this invention comprises the following overall process for the detection of target nucleic acids of a preselected sequence: a) Using the polymerase chain reaction (PCR) nucleic acid amplification method described in U.S. 4,683,202, incorporated herein by reference, two specific nucleic acid sequences, within the preselected sequence, are amplified by first annealing the denatured target nucleic acid present in the sample with two sets of oligonucleotide primers complementary to the specific nucleic acid sequences. These primers are designed such that one primer of each set of primers contains a LoxP sequence attached to its 5'-end. The LoxP sequence is defined by a 34 -nucleotide sequence
5' ...ATAACTTCGTATAGCATACATTATACGAAGTTAT...3' . [See Sternberg et al., J. Mol. Biol., Volume 197, 197-212 (1986) .] The specific nucleic acid sequences are positioned such that when either sequence is amplified under amplification conditions, the extension product of either sequence cannot serve as a template for the synthesis of the other sequence. During amplification, each extension product formed from each set of primers is complementary to one of the two specific nucleic acid sequences within the preselected nucleic acid sequence and is a template for further primer extension. This process is then repeated as necessary in order to produce the desired amount of primer extension products for detection and/or measurement. b) Adding the recombinase enzyme Cre to the products of the two separate amplification reactions, allowing the enzyme to combine the amplification product from the first amplification with the amplification product from the second amplification. The resulting product is of a length of the combination of the two specific nucleic acid sequences plus 34 additional nucleotides. c) Detecting the product of the above step by, for example, gel electrophoresis . Such detection can differentiate between the desired combination product on the one hand and the combination products formed from the coupling of each amplification product with itself. The term "PCR" as used herein in referring to the process of amplifying target nucleic acid sequences employing primer oligonucleotides to produce by enzymatic means a greatly increased number of copies of a small portion of the target nucleic acid is described in U.S. patent 4,683,202. The PCR target amplification reaction requires approximately 20 to 30 repeat cycles in order to produce a sufficient quantity of the amplified target nucleic acid for further hybridization. Denaturation of the amplified nucleic acid can be accomplished by treatment with alkali, acid, chaotropic agents, or heat, although the preferred method is to place the amplified target nucleic acid in a boiling water bath for at least 10 minutes followed by a chilled water bath (4°C) for at least two minutes.
The Example below exemplifies the invention.
EXAMPLE Dftt-.ftntinn of HIV T
A. Amplification of Target Nucleic Acid by PCR
The procedure as described in U.S. Patent 4,683,202 and in a product bulletin for GeneA p DNA Amplification Reagent Kit (#N801-0043) can be followed utilizing the following specific conditions and reagents. Two sequences of the HIV I genome can be selected to be amplified. The first is a 103-nucleotide base sequence located within the GAG pl7 region of HIV I, incorporated into a plasmid (the plasmid incorporating most of the HIV I genome is designated pBH10-R3), and can be amplified using primers A and B as shown below:
5* ..ATAACTTCGTATAGCATACATTATACGAAGTTATTGGGCAAGCAGGGAGCTAGG ..3'
Primer A 5' ..ATAACTTCGTATAGCATACATTATACGAAGTTATTCTGAAGGGATGGTTGTACG ..3'
The second is a 160-base region also located within the GAG pl7 region of HIV I, incorporated into a plasmid (the plasmic incorporating most of the HIV I genome is designated pBH10-R3) , and can be amplified using Primers
C and D as shown below:
.3' Primer C
Primer D Aliquots of serial dilutions (lxl0+7, lxl0+6, lxl0+5, lxl0+4, lxl0+3, lxl0+2, lxl0+1, and zero copies) of plasmid pBH10-R3 can be amplified using PCR. Each aliquot can be combined with a buffer 200 μM in each of dATP, dTTP, dCTP, and dGTP, 1.0 μM in each of Primers A,
B, C, and D, and containing 1 μg of human placental DNA/reaction and 2.5 units of a DNA polymerase, in a total reaction volume of 100 μl.
Each reaction mixture can then be temperature cycled as described in the product bulletin thirty (30) times. This process is expected to result in the estimated increase in the number of target molecules by lxl0+5 to lxl0+6.
The products of the amplification reactions can be placed onto a 6% acrylamide gel run under standard conditions. After electrophoresis, the gel can be soaked in a 10 μg/ml solution of ethidium bromide in 10 mM Tris, pH 7.0, for 15 minutes. The gel can then be rinsed in 10 mM Tris, pH 7.0, and the resulting product bands can be detected and/or measured by irradiating the gel at 302 nm and visualizing the fluorescent bands produced.
|Brevet cité||Date de dépôt||Date de publication||Déposant||Titre|
|EP0246864B1 *||19 mai 1987||13 juil. 1994||Bio-Rad Laboratories, Inc.||Hybridisation probes|
|US4683202 *||25 oct. 1985||27 nov. 1990||Cetus Corp||Titre non disponible|
|1||*||Journal of Molecular Biology, Volume 187, issued 1986 pages 197-212; STERNBERG et al.: "Bacteriophage P1 cre Gene and its Regulatory Region, "Evidence for Multiple Promoters and Regulation by DNA Methylation".|
|Brevet citant||Date de dépôt||Date de publication||Déposant||Titre|
|WO2003029489A1 *||3 oct. 2002||10 avr. 2003||Iseao Technologies Limited||Methods for detection of target molecules and molecular interactions|
|EP0630973A2 *||11 mai 1994||28 déc. 1994||Johnson & Johnson Clinical Diagnostics, Inc.||Diagnostic compositions, elements, methods & test kits for amplification & detection of two or more DNA's using primers having matched melting temperatures|
|EP0630973A3 *||11 mai 1994||26 avr. 1995||Eastman Kodak Co||Diagnostic compositions, elements, methods & test kits for amplification & detection of two or more DNA's using primers having matched melting temperatures.|
|EP1025217A1 *||26 oct. 1998||9 août 2000||Life Technologies, Inc.||Recombinational cloning using nucleic acids having recombination sites|
|EP1025217A4 *||26 oct. 1998||13 nov. 2002||Life Technologies Inc||Recombinational cloning using nucleic acids having recombination sites|
|EP1229113A2 *||7 juin 1996||7 août 2002||Invitrogen Corporation||Recombinational cloning using engineered recombination sites|
|EP1229113A3 *||7 juin 1996||27 nov. 2002||Invitrogen Corporation||Recombinational cloning using engineered recombination sites|
|US5591609 *||3 févr. 1995||7 janv. 1997||Replicon, Inc.||Methods for the isothermal amplification of nucleic acid molecules|
|US5614389 *||26 sept. 1995||25 mars 1997||Replicon, Inc.||Methods for the isothermal amplification of nucleic acid molecules|
|US5733733 *||1 févr. 1996||31 mars 1998||Replicon, Inc.||Methods for the isothermal amplification of nucleic acid molecules|
|US5834202 *||5 août 1997||10 nov. 1998||Replicon, Inc.||Methods for the isothermal amplification of nucleic acid molecules|
|US6218152||9 nov. 1998||17 avr. 2001||Replicon, Inc.||In vitro amplification of nucleic acid molecules via circular replicons|
|US6261808||8 sept. 2000||17 juil. 2001||Replicon, Inc.||Amplification of nucleic acid molecules via circular replicons|
|US6448017||9 juil. 2001||10 sept. 2002||Replicon, Inc.||In vitro amplification of nucleic acid molecules via circular replicons|
|US6720140||4 févr. 2000||13 avr. 2004||Invitrogen Corporation||Recombinational cloning using engineered recombination sites|
|US6740745||14 mai 2002||25 mai 2004||Replicon, Inc.||In vitro amplification of nucleic acid molecules via circular replicons|
|US6828093||24 juil. 1998||7 déc. 2004||Baylor College Of Medicine||Rapid subcloning using site-specific recombination|
|US6964861||12 nov. 1999||15 nov. 2005||Invitrogen Corporation||Enhanced in vitro recombinational cloning of using ribosomal proteins|
|US8883988||28 juin 2012||11 nov. 2014||Life Technologies Corporation||Compositions for use in recombinational cloning of nucleic acids|
|US8945884||13 mai 2013||3 févr. 2015||Life Technologies Corporation||Methods and compositions for synthesis of nucleic acid molecules using multiplerecognition sites|
|US9309520||19 déc. 2014||12 avr. 2016||Life Technologies Corporation||Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites|
|US9534252||14 sept. 2012||3 janv. 2017||Life Technologies Corporation||Nucleic acid molecules containing recombination sites and methods of using the same|
|Classification internationale||C12Q1/70, C12Q1/68|
|Classification coopérative||C12Q1/686, C12Q1/703|
|Classification européenne||C12Q1/68D4, C12Q1/70B2B|
|4 oct. 1990||AK||Designated states|
Kind code of ref document: A1
Designated state(s): AU JP NO
|4 oct. 1990||AL||Designated countries for regional patents|
Kind code of ref document: A1
Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE
|19 sept. 1991||WWE||Wipo information: entry into national phase|
Ref document number: 1990905265
Country of ref document: EP
|15 janv. 1992||WWP||Wipo information: published in national office|
Ref document number: 1990905265
Country of ref document: EP
|15 janv. 1992||WWW||Wipo information: withdrawn in national office|
Ref document number: 1990905265
Country of ref document: EP
|11 juin 1992||WR||Later publication of a revised version of an international search report|